SCHEMBL23217892

SCHEMBL23217892

O=C(CC(F)(F)F)c1cccc(Br)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.52
ALDH1A1 P00352 3/20 0.49
GLA P06280 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.46
TP53 P04637 1/20 0.46
HPGD P15428 1/20 0.44
ACHE P22303 1/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
NPC1 O15118 3/20 0.43
MGAM O43451 1/20 0.43
AMY1A P0DUB6 1/20 0.43
GAA P10253 1/20 0.43
SI P14410 1/20 0.43
MGAM2 Q2M2H8 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
C1S P09871 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
TP53BP1 Q12888 1/20 0.42
RAB9A P51151 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL244595 0.83 PARP1 (0.57) PARP1ALDH1A1GLAL3MBTL1TP53
SCHEMBL2791794 0.83 PARP1 (0.49) PARP1ALDH1A1GLAL3MBTL1TP53
SCHEMBL10013509 0.81 NOTUM (0.40) PARP1ALDH1A1MEN1KMT2AMAPT
SCHEMBL5255868 0.81 PARP1 (0.50) PARP1ALDH1A1GLAL3MBTL1TP53
SCHEMBL5255871 0.81 PARP1 (0.50) PARP1ALDH1A1GLAL3MBTL1TP53
SCHEMBL11768399 0.80 CA12 (0.52) PARP1ALDH1A1ACHEMEN1KMT2A
SCHEMBL4906913 0.79 PLOD2 (0.54) PARP1ALDH1A1GLAL3MBTL1TP53
SCHEMBL30758864 0.79 PARP1 (0.61) PARP1ALDH1A1GLAL3MBTL1TP53
SCHEMBL11775697 0.79 PBRM1 (0.50) ALDH1A1ACHENPC1SMN1; SMN2RECQL
SCHEMBL23241849 0.79 C1S (0.52) PARP1ALDH1A1GLAL3MBTL1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250275991-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-09-04 US disclosed
EP-4041717-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114555570-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-27 CN disclosed
WO-2021072156-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072156-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250275991-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB PARP1 3043/4885ALDH1A1 3388/4885GLA 1157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.